5505 MOREHOUSE DRIVE, SAN DIEGO, CA
Reports Full Year 2025 Financial Results and Recent Business Highlights
CFO Appointment - Thad Huston Named Chief Financial Officer
Board Appointment - Elaine Sorg Joins Artiva Biotherapeutics Board
Artiva Biotherapeutics Enters RSU Exchange Agreements with Executives
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
Earnings Release
News, Material Contracts
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
S-1MEF